- $39.70bn
- $36.36bn
- $2.19bn
- 50
- 14
- 97
- 54
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 43.97 | ||
| PEG Ratio (f) | 2.86 | ||
| EPS Growth (f) | 18.18% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.22 | ||
| Price to Tang. Book | 7.47 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 18.12 | ||
| EV to EBITDA | 10,337.65 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -0.39% | ||
| Return on Equity | 17.36% | ||
| Operating Margin | -0.99% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 41.24 | 497.28 | 410.75 | 1,226.32 | 2,190.23 | 3,566.94 | 4,664.42 | 94.61% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | -6.45 | +69.97 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Directors
- Peter Verhaeghe NEC (62)
- Tim Van Hauwermeiren CEO (49)
- Werner Lanthaler NVC (52)
- Karl Gubitz CFO
- Keith Woods COO (53)
- Hans de Haard CSO (61)
- Arjen Lemmen VBD (36)
- Dirk Beeusaert GCN (57)
- Marc Schorpion DHR (63)
- Wim Parys OTH (61)
- Andria Wilk OTH (48)
- Yvonne Greenstreet NED
- James Daly NID (59)
- Joseph deBethizy NID (70)
- Pamela Klein NID (60)
- Anthony Rosenberg NID (68)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 25th, 2008
- Public Since
- July 10th, 2014
- No. of Employees
- 1,599
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 61,059,563
- Address
- Laarderhoogtweg 25, AMSTERDAM, 1101 EB
- Web
- https://www.argenx.com/
- Phone
- +31 763030
- Auditors
- Deloitte Accountants B.V.
Upcoming Events for ARGX
Similar to ARGX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
As of Today at 19:19 UTC, shares in argenx SE are trading at $649.67. This share price information is delayed by 15 minutes.
Shares in argenx SE last closed at $649.67 and the price had moved by +65.13% over the past 365 days. In terms of relative price strength the argenx SE share price has outperformed the S&P500 Index by +48.9% over the past year.
The overall consensus recommendation for argenx SE is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreargenx SE does not currently pay a dividend.
argenx SE does not currently pay a dividend.
argenx SE does not currently pay a dividend.
To buy shares in argenx SE you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $649.67, shares in argenx SE had a market capitalisation of $39.70bn.
Here are the trading details for argenx SE:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ARGX
Based on an overall assessment of its quality, value and momentum argenx SE is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in argenx SE is $746.47. That is 14.9% above the last closing price of $649.67.
Analysts covering argenx SE currently have a consensus Earnings Per Share (EPS) forecast of $11.96 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like argenx SE. Over the past six months, its share price has outperformed the S&P500 Index by +9.58%.
As of the last closing price of $649.67, shares in argenx SE were trading +11.61% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The argenx SE PE ratio based on its reported earnings over the past 12 months is 43.97. The shares last closed at $649.67.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
argenx SE's management team is headed by:
- Peter Verhaeghe - NEC
- Tim Van Hauwermeiren - CEO
- Werner Lanthaler - NVC
- Karl Gubitz - CFO
- Keith Woods - COO
- Hans de Haard - CSO
- Arjen Lemmen - VBD
- Dirk Beeusaert - GCN
- Marc Schorpion - DHR
- Wim Parys - OTH
- Andria Wilk - OTH
- Yvonne Greenstreet - NED
- James Daly - NID
- Joseph deBethizy - NID
- Pamela Klein - NID
- Anthony Rosenberg - NID